Glycoside analogs of β-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry

Antiviral Research

Volumn 80, Issue 1, 2008, Pages 54-61

  Garg, Himanshu ^a   Francella, Nicholas ^a   Tony, Kurissery A ^b   Augustine, Line A ^b   Barchi Jr , Joseph J ^a   Fantini, Jacques ^c   Puri, Anu ^a   Mootoo, David R ^b   Blumenthal, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Anti HIV; Envelope glycoprotein; Fusion; Galactosyl Ceramide; Glycosides; HIV 1

Indexed keywords

BETA GALACTOSYLCERAMIDE DERIVATIVE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GALACTOSE; GALACTOSYLCERAMIDE; GLYCOLIPID; GLYCOPROTEIN GP 120; GLYCOSIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING ASSAY; CELL FUSION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; VESICULAR STOMATITIS VIRUS; VIRUS ATTACHMENT; VIRUS ENTRY;

ANTI-HIV AGENTS; GALACTOSYLCERAMIDES; GLYCOSIDES; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MEMBRANE FUSION; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 50049131645     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.04.004     Document Type: Article

References (28)

1. Augustin L.A., Fantini J., and Mootoo D.R. C-Glycoside analogues of beta-galactosylceramide with a simple ceramide substitute: synthesis and binding to HIV-1 gp120. Bioorg. Med. Chem. 14 (2006) 1182-1188
2. Barrientos L.G., O'keefe B.R., Bray M., Sanchez A., Gronenborn A.M., and Boyd M.R. Cyanovirin-N binds to the viral surface glycoprotein, GP1, 2 and inhibits infectivity of Ebola virus. Antiviral Res. 58 (2003) 47-56
3. Bhat S., Mettus R.V., Reddy E.P., Ugen K.E., Srikanthan V., Williams W.V., and Weiner D.B. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275. AIDS Res. Hum. Retroviruses 9 (1993) 175-181
4. Chang L.C., and Bewley C.A. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants. J. Mol. Biol. 318 (2002) 1-8
5. Dey B., Lerner D.L., Lusso P., Boyd M.R., Elder J.H., and Berger E.A. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J. Virol. 74 (2000) 4562-4569
6. Esté J.A., and Telenti A. HIV entry inhibitors. Lancet 370 (2007) 81-88
7. Fantini J. How sphingolipids bind and shape proteins: molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains. Cell Mol. Life Sci. 60 (2003) 1027-1032
8. Fantini J., Hammache D., Delézay O., Yahi N., André-Barrès C., Rico-Lattes I., and Lattes A. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry. J. Biol. Chem. 272 (1997) 7245-7252
9. Fantini J., Hammache D., Piéroni G., and Yahi N. Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion. Glycoconj. J. 17 (2000) 199-204
10. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614 (2003) 36-50
11. Garmy N., Taïeb N., Yahi N., and Fantini J. Interaction of cholesterol with sphingosine: physicochemical characterization and impact on intestinal absorption. J. Lipid Res. 46 (2005) 36-45
12. Hammache D., Piéroni G., Yahi N., Delézay O., Koch N., Lafont H., Tamalet C., and Fantini J. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J. Biol. Chem. 273 (1998) 7967-7971
13. Kuipers M.E., Huisman J.G., Swart P.J., de Béthune M.P., Pauwels R., Schuitemaker H., De Clercq E., and Meijer D.K. Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11 (1996) 419-429
14. Lund N., Branch D.R., Mylvaganam M., Chark D., Ma X.Z., Sakac D., Binnington B., Fantini J., Puri A., Blumenthal R., and Lingwood C.A. A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. AIDS 20 (2006) 333-343
15. Mahfoud R., Mylvaganam M., Lingwood C.A., and Fantini J. A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction. J. Lipid Res. 43 (2002) 1670-1679
16. Marsh D. Lateral pressure in membranes. Biochim. Biophys. Acta 1286 (1996) 183-223
17. Mkrtchyan S.R., Markosyan R.M., Eadon M.T., Moore J.P., Melikyan G.B., and Cohen F.S. Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J. Virol. 79 (2005) 11161-11169
18. Nehete P.N., Arlinghaus R.B., and Sastry K.J. Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120. J. Virol. 67 (1993) 6841-6846
19. Nehete P.N., Vela E.M., Hossain M.M., Sarkar A.K., Yahi N., Fantini J., and Sastry K.J. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains. Antiviral Res. 56 (2002) 233-251
20. Rawat S.S., Johnson B.T., and Puri A. Sphingolipids: modulators of HIV-1 infection and pathogenesis. Biosci. Rep. 25 (2005) 329-343
21. Rawat S.S., Viard M., Gallo S.A., Blumenthal R., and Puri A. Sphingolipids, cholesterol, and HIV-1: a paradigm in viral fusion. Glycoconj. J. 23 (2006) 189-197
22. Rider C.C., Coombe D.R., Harrop H.A., Hounsell E.F., Bauer C., Feeney J., Mulloy B., Mahmood N., Hay A., and Parish C.R. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33 (1994) 6974-6980
23. Taïeb N., Yahi N., and Fantini J. Rafts and related glycosphingolipid-enriched microdomains in the intestinal epithelium: bacterial targets linked to nutrient absorption. Adv. Drug Deliv. Rev. 56 (2004) 779-794
24. Tanahashi E., Murase K., Shibuya M., Igarashi Y., Ishida H., Hasegawa A., and Kiso M. Synthetic studies on selectin ligands/inhibitors: A systematic synthesis of sulfatide and its higher congeners carrying 2-(tetradecyl)hexadecyl group as a ceramide substitute. J. Carbohydr. Chem. 16 (1997) 831-858
25. Villard R., Hammache D., Delapierre G., Fotiadu F., Buono G., and Fantini J. Asymmetric synthesis of water-soluble analogues of galactosylceramide, an HIV-1 receptor: new tools to study virus-glycolipid interactions. Chembiochem 3 (2002) 517-525
26. Wang W., Cole A.M., Hong T., Waring A.J., and Lehrer R.I. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J. Immunol. 170 (2003) 4708-4716
27. Xiong C., O'keefe B.R., Botos I., Wlodawer A., and McMahon J.B. Overexpression and purification of scytovirin, a potent, novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Protein Expr. Purif. 46 (2006) 233-239
28. Yahi N., Sabatier J.M., Nickel P., Mabrouk K., Gonzalez-Scarano F., and Fantini J. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J. Biol. Chem. 269 (1994) 24349-24353